Tracey Ramsay News Today

/CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay...

Approval is based on results from three Phase 3 studies: two for induction and one for maintenance 1,2,3In clinical trials, patients taking RINVOQ achieved the primary endpoint of clinical remission ...

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at... | May 9, 2023

- QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of

Timing of elimination of the hepatitis C virus (HCV) in Canadas provinces indicates 70% of provinces could reach the World Health Organizations (WHO) HCV...

(RTTNews) - AbbVie (ABBV) announced Health Canada approval for SKYRIZI for the treatment of adults with moderately to severely active Crohns dise...

MAVIRET can now be used as an 8-week, once-daily paediatric granule formulation option in treatment-naïve, without cirrhosis or with compensated cirrhosis, chronic Hepatitis C paediatric... | June 22, 2022

AbbVie, a research-based global biopharmaceutical company, announced Health Canada has approved SKYRIZI® (risankizumab), for the treatment of adult

/CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced Health Canada has approved SKYRIZI® (risankizumab), for the treatment...

AbbVie and the University of Toronto Establish Endowed Chair in Ethnodermatology - read this article along with other careers information, tips and advice on BioSpace